Prospector Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,439
| Closed | -$528K | – | 20 |
|
|
2025
Q3 | $528K | Sell |
3,439
-1,254
| -27% | -$190K | 0.06% | 90 |
|
|
2025
Q2 | $656K | Buy |
4,693
+1,165
| +33% | +$163K | 0.08% | 88 |
|
|
2025
Q1 | $519K | Hold |
3,528
| – | – | 0.06% | 90 |
|
|
2024
Q4 | $462K | Hold |
3,528
| – | – | 0.05% | 94 |
|
|
2024
Q3 | $550K | Buy |
3,528
+178
| +5% | +$28.7K | 0.06% | 95 |
|
|
2024
Q2 | $523K | Hold |
3,350
| – | – | 0.06% | 95 |
|
|
2024
Q1 | $454K | Buy |
3,350
+185
| +6% | +$24.5K | 0.05% | 96 |
|
|
2023
Q4 | $426K | Buy |
3,165
+222
| +8% | +$28.9K | 0.05% | 90 |
|
|
2023
Q3 | $399K | Hold |
2,943
| – | – | 0.05% | 91 |
|
|
2023
Q2 | $421K | Hold |
2,943
| – | – | 0.06% | 87 |
|
|
2023
Q1 | $408K | Hold |
2,943
| – | – | 0.06% | 96 |
|
|
2022
Q4 | $399K | Hold |
2,943
| – | – | 0.05% | 103 |
|
|
2022
Q3 | $323K | Hold |
2,943
| – | – | 0.05% | 104 |
|
|
2022
Q2 | $389K | Hold |
2,943
| – | – | 0.06% | 97 |
|
|
2022
Q1 | $390K | Sell |
2,943
-87
| -3% | -$10.4K | 0.05% | 101 |
|
|
2021
Q4 | $353K | Hold |
3,030
| – | – | 0.04% | 106 |
|
|
2021
Q3 | $364K | Hold |
3,030
| – | – | 0.05% | 105 |
|
|
2021
Q2 | $363K | Hold |
3,030
| – | – | 0.05% | 107 |
|
|
2021
Q1 | $301K | Hold |
3,030
| – | – | 0.04% | 114 |
|
|
2020
Q4 | $303K | Sell |
3,030
-13,625
| -82% | -$1.44M | 0.04% | 114 |
|
|
2020
Q3 | $1.82M | Sell |
16,655
-425
| -2% | -$47.3K | 0.27% | 81 |
|
|
2020
Q2 | $1.81M | Buy |
17,080
+1,325
| +8% | +$137K | 0.31% | 80 |
|
|
2020
Q1 | $1.41M | Sell |
15,755
-245
| -2% | -$23.1K | 0.27% | 76 |
|
|
2019
Q4 | $1.6M | Hold |
16,000
| – | – | 0.22% | 86 |
|
|
2019
Q3 | $1.43M | Sell |
16,000
-6,950
| -30% | -$603K | 0.21% | 91 |
|
|
2019
Q2 | $1.9M | Hold |
22,950
| – | – | 0.26% | 87 |
|
|
2019
Q1 | $1.86M | Sell |
22,950
-6,950
| -23% | -$548K | 0.28% | 84 |
|
|
2018
Q4 | $2.27M | Hold |
29,900
| – | – | 0.35% | 80 |
|
|
2018
Q3 | $2.37M | Hold |
29,900
| – | – | 0.33% | 85 |
|
|
2018
Q2 | $2.1M | Hold |
29,900
| – | – | 0.29% | 93 |
|
|
2018
Q1 | $2.09M | Hold |
29,900
| – | – | 0.31% | 88 |
|
|
2017
Q4 | $2.08M | Hold |
29,900
| – | – | 0.3% | 87 |
|
|
2017
Q3 | $2.03M | Buy |
29,900
+7,500
| +33% | +$474K | 0.31% | 85 |
|
|
2017
Q2 | $1.53M | Sell |
22,400
-900
| -4% | -$58.8K | 0.24% | 93 |
|
|
2017
Q1 | $1.45M | Hold |
23,300
| – | – | 0.22% | 95 |
|
|
2016
Q4 | $1.27M | Hold |
23,300
| – | – | 0.19% | 103 |
|
|
2016
Q3 | $1.53M | Sell |
23,300
-29,100
| -56% | -$1.9M | 0.24% | 100 |
|
|
2016
Q2 | $3.16M | Buy |
52,400
+50
| +0.1% | +$2.9K | 0.54% | 73 |
|
|
2016
Q1 | $2.95M | Buy |
52,350
+5,450
| +12% | +$327K | 0.51% | 72 |
|
|
2015
Q4 | $3.19M | Buy |
+46,900
| New | +$3.07M | 0.57% | 68 |
|
Other funds holding AZN
Prospector Partners's AZN Position: Q4 2025 in Review
Prospector Partners sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 3,439 shares — an estimated $528K sold.
Prospector Partners first reported a position in AZN in Q4 2015 and held it in 40 quarters. The position peaked at $3.19M in Q4 2015. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.
- Prospector Partners reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
- Prospector Partners sold 3,439 AstraZeneca shares in Q4 2025, an estimated $528K.
- Prospector Partners first reported a position in AstraZeneca in Q4 2015 and held it in 40 quarters.
- Prospector Partners's AstraZeneca position peaked at $3.19M in Q4 2015.
- 1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.
Based on Prospector Partners's 13F filing for Q4 2025, filed 13 Feb 2026.